Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Alpha FX restarts relationship; Atalaya resources up

Tue, 05th Apr 2022 21:39

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Alpha FX Group PLC - London-based foreign exchange risk management and international payments - Restarts trading relationship with unnamed "key" Norwegian client. Entered settlement agreement with client in March 2020 at onset of Covid pandemic, where the client was required to make weekly repayments until June 2022 in respect of their obligations for unpaid margins. "Since this date, the client's financial standing has continued to strengthen, and they have consistently met all 104 of their weekly repayment obligations on time. As a result, the gross balance outstanding as at April 1, 2022 has been reduced to GBP2.9 million," company says. Notes it will allow clients to pay outstanding amount over rest of 2022, extending deadline past June 2022.

----------

Marlowe PLC - London-based company focused on business safety and regulatory compliance - Says at Capital Markets Day its trading has been "strong" and expects to meet 2024 strategic and financial targets "materially ahead of schedule". Company says the "significant development" in building its compliance platform - which now encompasses intelligence, consultancy, software and assurance - the reason behind strong trading.

----------

Aferian PLC - Leeds-based video streaming - Acquires 100% share capital of Exabre Ltd, trading as The Filter, a UK-headquartered AI-powered video recommendation service. Initial consideration of deal will GBP1.5 million in cash, with up to GBP2.5 million subject to achieving certain annual recurring revenue growth at increments of additional ARR of GBP500,000. Company says: "The Filter's technology will significantly accelerate the roadmap of 24i's video streaming platform by adding enhanced analytics, recommendations and personalisation to its existing data analytics services. 24i will also market The Filter's managed service solution to its existing OTT and Pay TV customers and prospects as a standalone service."

----------

Glantus Holdings PLC - Dublin-based accounts payable automation and analytics - Agrees new partnership with TealBook, a supplier data firm that powers e-procurement technology. "This partnership will enable customers of both parties to access robust supplier information and insights and stronger AP intelligence," company explains. Adds: "The referral party vendor and supplier information through TealBook's comprehensive supplier intelligence capabilities will enable TealBook customers to utilize the Glantus data analytics solution to understand opportunities for efficiency and risk mitigation within their AP operations and payments."

----------

Redx Pharma PLC - Cheshire-based cancer and fibrosis drug developer - Agrees collaboration with the Garvan Institute of Medical Research, an Australian medical research institute, which expands on company's preclinical work already underway. "The collaboration aims to better understand treatments that could lead to increased patient survival in currently very poorly treated highly fibrotic cancers, such as pancreatic cancer," company says. Adds: "Through this collaboration, Redx and the Garvan will develop an enhanced understanding of cancer-associated fibrosis through detailed scientific studies utilising patient-derived tumour tissue grown in mice, which is thereby able to mimic human disease as closely as possible."

----------

e-Therapeutics PLC - Oxford, England-based computational drug discovery - Enters research collaboration agreement with iTeos Therapeutics Inc, a clinical-stage biopharmaceutical company focused on discovery and development of a new generation of immuno-oncology therapeutics. "The collaboration will focus on the discovery of novel therapeutic approaches and targets in immuno-oncology. e-therapeutics will remain free to explore additional collaborations in the space," company explains. e-therapeutics will receive upfront and near-term cash payments material to the revenue of the company.

----------

Atalaya Mining PLC - copper miner in Spain - Sees "significant" increase in mineral resources at Proyecto Masa Valverde. PMV is located in the Iberian Pyrite Belt of southern Spain. PMV consists of two deposits, Masa Valverde and Majadales. Sees increase in tonnage and contained copper, silver and gold from prior estimate of 42%, 33%, 26% and 34%, respectively. Masa Valverde initial indicated mineral resource now 16.9 million tonnes at 0.66% copper, 1.55% zinc, 0.65% lead, and 27 grammes per tonne silver and 0.55 grammes per tonne gold. Chief Executive Alberto Lavandeira says: "We remain excited about the continued exploration potential at PMV, given the many anomalies our exploration team has identified. We hope to make further discoveries, building on our success in discovering the Majadales deposit, which is shallower and higher grade than Masa Valverde and thus may play a key role in optimising future development scenarios."

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
11 Mar 2020 10:23

Redx Pharma Optimistic As Loss Narrows And Cancer Trial Progresses

Redx Pharma Optimistic As Loss Narrows And Cancer Trial Progresses

Read more
28 Feb 2020 18:47

UPDATE: Redx Pharma To Get GBP26 Million Injection Amid No Yesod Bid

UPDATE: Redx Pharma To Get GBP26 Million Injection Amid No Yesod Bid

Read more
28 Feb 2020 18:08

No Redx Pharma Takeover As Yesod Opts Not To Make Offer

No Redx Pharma Takeover As Yesod Opts Not To Make Offer

Read more
14 Feb 2020 17:11

UK Regulator Extends Deadline For Possible Redx Pharma Cash Offer

UK Regulator Extends Deadline For Possible Redx Pharma Cash Offer

Read more
28 Jan 2020 14:15

UK Regulator Extends Deadline For Possible Redx Pharma Cash Offer

UK Regulator Extends Deadline For Possible Redx Pharma Cash Offer

Read more
24 Jan 2020 11:51

Moulton Goodies Raises Stake In Redx Pharma To 42% From 18%

Moulton Goodies Raises Stake In Redx Pharma To 42% From 18%

Read more
9 Jan 2020 16:02

Redx Pharma nominates next drug development candidate

(Sharecast News) - Drug discovery and development company Redx Pharma announced the nomination of RXC007 as its next drug development candidate for the treatment of fibrosis on Thursday.

Read more
9 Jan 2020 11:17

Redx Pharma Nominates Another Anti-Fibrosis Drug Candidate

Redx Pharma Nominates Another Anti-Fibrosis Drug Candidate

Read more
31 Dec 2019 10:34

UK WINNERS & LOSERS SUMMARY: Redx Surges On Potential Takeover Offer

UK WINNERS & LOSERS SUMMARY: Redx Surges On Potential Takeover Offer

Read more
31 Dec 2019 09:12

Redx Pharma Shares Soar On Discussions Over Possible Takeover Offer

Redx Pharma Shares Soar On Discussions Over Possible Takeover Offer

Read more
31 Dec 2019 08:51

LONDON MARKET OPEN: Stocks Start Mostly Lower Amid Profit Taking

LONDON MARKET OPEN: Stocks Start Mostly Lower Amid Profit Taking

Read more
19 Nov 2019 12:29

Redx collaboration with MDC awarded Innovate UK funding

(Sharecast News) - Redx Pharma announced on Tuesday that Innovate UK has awarded biomedical catalyst funding to Redx and Medicines Discovery Catapult (MCD).

Read more
19 Nov 2019 11:53

Redx Pharma Secures Funding To Develop Lung Condition Therapies

Redx Pharma Secures Funding To Develop Lung Condition Therapies

Read more
19 Aug 2019 10:22

Redx Pharma Gets Approval To Escalate Dose In RXC004 Study

(Alliance News) - Redx Pharma PLC on Monday said it has successfully completed dosing of the first cohort of patients in its ongoing phase 1/2 study with RXC004.RXC004 is an oral porcupine

Read more
19 Aug 2019 09:43

Redx Pharma gets green light to escalate dose in RXC004 study

(Sharecast News) - Drug discovery and development company Redx Pharma has successfully completed dosing of the first cohort of patients in its ongoing phase 1 and 2 study with 'RXC004', it announced on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.